The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors
Open accessAbstract
Therapies using T cells that are programmed to express chimeric antigen receptors (CAR T cells) consistently produce positive results in patients with hematologic malignancies. However, CAR T cell treatments are less effective in solid tumors for several reasons. First, lymphocytes do not efficiently target CAR T cells; second, solid tumors create an immunosuppressive microenvironment that inactivates T cell responses; and third, solid cancers are typified by phenotypic diversity and thus include cells that do not express proteins targeted by the engineered receptors, enabling the formation of escape variants that elude CAR T cell targeting. Here, we have tested implantable biopolymer devices that deliver CAR T cells directly to the surfaces of solid tumors, thereby exposing them to high concentrations of immune cells for a substantial time period. In immunocompetent orthotopic mouse models of pancreatic cancer and melanoma, we found that CAR T cells can migrate from biopolymer scaffolds and eradicate tumors more effectively than does systemic delivery of the same cells. We have also demonstrated that codelivery of stimulator of IFN genes (STING) agonists stimulates immune responses to eliminate tumor cells that are not recognized by the adoptively transferred lymphocytes. Thus, these devices may improve the effectiveness of CAR T cell therapy in solid tumors and help protect against the emergence of escape variants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
NFAT proteins: key regulators of T-cell development and function
Macian, F. (2005) · Nature Reviews Immunology · doi:10.1038/nri1632 · Cited by 1,569
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Cancer Research Communications
(2021) · doi:10.1158/1078-0432 · Cited by 1,532
Parkhurst, M. R., Yang, J. C., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,020
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 982
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4306 · Cited by 720
Boontheekul, T., Kong, H.-J., & Mooney, D. J. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.06.044 · Cited by 659
Deciphering and Reversing Tumor Immune Suppression
Motz, G. T., & Coukos, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.005 · Cited by 598
Kim, J., Li, W. A., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541
Biopolymer implants enhance the efficacy of adoptive T-cell therapy
Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2015) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 439
Self-citationAlginate type and RGD density control myoblast phenotype
Rowley, J. A., & Mooney, D. J. (2002) · Journal of Biomedical Materials Research · doi:10.1002/jbm.1287 · Cited by 437
Injectable cryogel-based whole-cell cancer vaccines
Bencherif, S. A., Warren Sands, R., Ali, O. A., Li, W. A., Lewin, S. A., Braschler, T. M., Shih, T.-Y., Verbeke, C. S., Bhatta, D., Dranoff, G., et al. (2015) · Nature Communications · doi:10.1038/ncomms8556 · Cited by 416
Managing Immune Checkpoint-Blocking Antibody Side Effects
Postow, M. A. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.76 · Cited by 403
Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
Hanson, M. C., Crespo, M. P., Abraham, W., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 381
STING-dependent cytosolic DNA sensing pathways
Barber, G. N. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.010 · Cited by 336
Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Tsang, K. Y., Poole, D. J., Parnes, H. L., Wright, J. J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70006-2 · Cited by 326
Läubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319
Polysaccharide‐modified synthetic polymeric biomaterials
Baldwin, A. D., & Kiick, K. L. (2010) · Peptide Science · doi:10.1002/bip.21334 · Cited by 287
Sheikh, N. A., Petrylak, D., Kantoff, P. W., dela Rosa, C., Stewart, F. P., Kuan, L.-Y., Whitmore, J. B., Trager, J. B., Poehlein, C. H., Frohlich, M. W., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1317-2 · Cited by 263
Coating of biomaterial scaffolds with the collagen-mimetic peptide GFOGER for bone defect repair
Wojtowicz, A. M., Shekaran, A., Oest, M. E., Dupont, K. M., Templeman, K. L., Hutmacher, D. W., Guldberg, R. E., & García, A. J. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2009.12.008 · Cited by 243
Kwong, B., Gai, S. A., Elkhader, J., Wittrup, K. D., & Irvine, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3343 · Cited by 197
Self-citationAugmenting Antitumor Immune Responses with Epigenetic Modifying Agents
Héninger, E., Krueger, T. E. G., & Lang, J. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00029 · Cited by 194
Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
Draper, L. M., Kwong, M. L. M., Gros, A., Stevanović, S., Tran, E., Kerkar, S., Raffeld, M., Rosenberg, S. A., & Hinrichs, C. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3341 · Cited by 183
Parkhurst, M., Gros, A., Pasetto, A., Prickett, T., Crystal, J. S., Robbins, P., & Rosenberg, S. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2680 · Cited by 182
Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street
Barrett, D. M., Grupp, S. A., & June, C. H. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500751 · Cited by 180
Chimeric NK-receptor–bearing T cells mediate antitumor immunotherapy
Zhang, T., Lemoi, B. A., & Sentman, C. L. (2005) · Blood · doi:10.1182/blood-2004-11-4365 · Cited by 157
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
John, L. B., Kershaw, M. H., & Darcy, P. K. (2013) · OncoImmunology · doi:10.4161/onci.26286 · Cited by 134
NKG2D CARs as Cell Therapy for Cancer
Sentman, C. L., & Meehan, K. R. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000029 · Cited by 111
Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma
Ghanem, G., & Journé, F. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.01.006 · Cited by 106
Johnson, D. B., Wallender, E. K., Cohen, D. N., Likhari, S. S., Zwerner, J. P., Powers, J. G., Shinn, L., Kelley, M. C., Joseph, R. W., & Sosman, J. A. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0092 · Cited by 106
Dobrenkov, K., Olszewska, M., Likar, Y., Shenker, L., Gunset, G., Cai, S., Pillarsetty, N., Hricak, H., Sadelain, M., & Ponomarev, V. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047324 · Cited by 92
Gang, A. O., Frøsig, T. M., Brimnes, M. K., Lyngaa, R., Treppendahl, M. B., Grønbæk, K., Dufva, I. H., Straten, P. T., & Hadrup, S. R. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.14 · Cited by 86
Kulkarni, R. R., Rasheed, M. A. U., Bhaumik, S. K., Ranjan, P., Cao, W., Davis, C. W., Marisetti, K., Thomas, S., Gangappa, S., Sambhara, S. R., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02273-14 · Cited by 83
Zhou, F., Li, X., Naylor, M. F., Hode, T., Nordquist, R. E., Alleruzzo, L., Raker, J., Lam, S. S. K., Du, N., Shi, L., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.029 · Cited by 82
Harrison, L. I., Astry, C. L., Kumar, S., & Yunis, C. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270007303766 · Cited by 80
Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities
Gray, P. M., Forrest, G., Wısnıewskı, T., Porter, G., Freed, D. C., DeMartino, J. A., Zaller, D. M., Guo, Z., Leone, J. W., Fu, T., et al. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.07.006 · Cited by 63
Muragaki, Y., Maruyama, T., Iseki, H., Tanaka, M., Shinohara, C., Takakura, K., Tsuboi, K., Yamamoto, T., Matsumura, A., Matsutani, M., et al. (2011) · Journal of neurosurgery · doi:10.3171/2011.4.jns10377 · Cited by 60
Epigenetic Modulators and the New Immunotherapies
Dear, A. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmcibr1514673 · Cited by 57
Targetless T cells in cancer immunotherapy
Straten, P. T., & Garrido, F. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0127-z · Cited by 38
Erskine, C. L., Henle, A. M., & Knutson, K. L. (2012) · Journal of Visualized Experiments · doi:10.3791/3683 · Cited by 37
The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas.
Bolander, Å., Agnarsdóttir, M., Strömberg, S., Pontén, F., Hesselius, P., Uhlén, M., & Bergqvist, M. (2008) · PubMed · Cited by 35
Albanesi, M., Mancardi, D. A., Macdonald, L. E., Iannascoli, B., Zitvogel, L., Murphy, A. J., Leusen, J. H. W., & Bruhns, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201511 · Cited by 35
Otsubo, D., Yamashita, K., Fujita, M., Nishi, M., Kimura, Y., Hasegawa, H., Suzuki, S., & Kakeji, Y. (2015) · PubMed · Cited by 30
Clavreul, A., Piard, N., Tanguy, J. Y., Gamelin, E., Rousselet, M., Leynia, P., & Meneï, P. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.11.017 · Cited by 28
Boross, P., Jansen, J. H. M., van Tetering, G., Nederend, M., Brandsma, A. M., Meyer, S., Torfs, E. C. W., van den Ham, H., Meulenbroek, L. A. P. M., de Haij, S., et al. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.02.005 · Cited by 15
Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer
Amato, R. J., & Stepankiw, M. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7654 · Cited by 9
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Translational Applications of Hydrogels
Correa, S., Grosskopf, A. K., Lopez Hernandez, H., Chan, D., Yu, A. C., Stapleton, L. M., & Appel, E. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01177 · Cited by 1,143
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 667
cGAS-STING, an important pathway in cancer immunotherapy
Jiang, M., Chen, P., Wang, L., Li, W., Chen, B., Liu, Y., Wang, H., Zhao, S., Ye, L., He, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00916-z · Cited by 647
Metadata
- Authors
- Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A. G., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-04-24
- Volume
- 127
- Issue
- 6
- Pages
- 2176-2191
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2607488814
- Cited by
- 336
- References
- 54
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.